Literature DB >> 1313515

A potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor.

X Emonds-Alt1, P Vilain, P Goulaouic, V Proietto, D Van Broeck, C Advenier, E Naline, G Neliat, G Le Fur, J C Brelière.   

Abstract

SR 48968 is a potent and selective non-peptide antagonist of the neurokinin A (NK2) receptor. SR 48968 selectively inhibited neurokinin A binding to its receptor and was a competitive antagonist of neurokinin A-mediated contraction of different isolated smooth muscle preparations from various species including human. In vivo, the compound inhibited the bronchoconstriction induced by neurokinin A in guinea pigs. SR 48968 can be used to study the physiological or pathological role of neurokinin A and may be useful in the treatment of neurokinin A-dependent pathology.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1313515     DOI： 10.1016/0024-3205(92)90352-p

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  52 in total

1.  Endothelium-dependent relaxation followed by contraction mediated by NK(1) receptors in precontracted rabbit intrapulmonary arteries.

Authors:  H Shirahase; M Kanda; K Kurahashi; S Nakamura
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

2.  Respiratory actions of tachykinins in the nucleus of the solitary tract: characterization of receptors using selective agonists and antagonists.

Authors:  S B Mazzone; D P Geraghty
Journal:  Br J Pharmacol       Date:  2000-03       Impact factor: 8.739

3.  Involvement of tachykinin receptors in sensitisation to cow's milk proteins in guinea pigs.

Authors:  J Gay; J Fioramonti; R Garcia-Villar; X Emonds-Alt; L Bueno
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

4.  Tachykinin-induced contraction of the guinea-pig isolated oesophageal mucosa is mediated by NK(2) receptors.

Authors:  K P Kerr; B Thai; I M Coupar
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

5.  Characterization of the endokinins: human tachykinins with cardiovascular activity.

Authors:  Nigel M Page; Nicola J Bell; Sheila M Gardiner; Isaac T Manyonda; Kerensa J Brayley; Philip G Strange; Philip J Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-25       Impact factor: 11.205

6.  Functional characterization of tachykinin NK1 receptors in the mouse uterus.

Authors:  Eva Patak; Jocelyn N Pennefather; Anna Fleming; Margot E Story
Journal:  Br J Pharmacol       Date:  2002-12       Impact factor: 8.739

Review 7.  Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning?

Authors:  Guy Griebel; Florian Holsboer
Journal:  Nat Rev Drug Discov       Date:  2012-05-18       Impact factor: 84.694

8.  The ventral tegmental area as a putative target for tachykinins in cardiovascular regulation.

Authors:  Kathleen Deschamps; Réjean Couture
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

9.  Two nonpeptide tachykinin antagonists act through epitopes on corresponding segments of the NK1 and NK2 receptors.

Authors:  U Gether; Y Yokota; X Emonds-Alt; J C Brelière; J A Lowe; R M Snider; S Nakanishi; T W Schwartz
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

10.  Study of SR 142801, a new potent non-peptide NK3 receptor antagonist on cardiovascular responses in conscious guinea-pig.

Authors:  A Roccon; D Marchionni; D Nisato
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.